Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 157,231

Document Document Title
WO/2018/129714A1
Provided are a monoclonal antibody resisting against PD-1 and applications thereof. The monoclonal antibody resisting against PD-1 comprises FCRN binding site regions having amino acid sequences shown in SEQ ID NO:5.  
WO/2018/132766A1
The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and ...  
WO/2018/132695A1
The invention provides chimeric antigen receptors (CARs) that specifically bind to the T-cell immunoglobulin and mucin domain 1 (TIM-1) protein. The invention further relates to modified immune cells, e.g., T or NK cells, comprising such...  
WO/2018/131659A1
An immunotherapeutic agent containing a heterocyclic compound represented by general formula (I) or a metabolite or pharmaceutically acceptable salt thereof as an active ingredient.  
WO/2018/129904A1
Disclosed are a benzodiazepine alkaloid compound and a pharmaceutically acceptable salt thereof, the structure of the compound being shown in general formula (I). In formula (I), R1, R2 and R3 independently are hydrogen, C1 ~4 alkyl or C...  
WO/2018/130790A1
The invention relates to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO : 1, said peptide having an amino acid sequence selected from the group consisting of: a) the seq...  
WO/2018/130868A1
This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment a...  
WO/2018/130659A1
The invention relates to apolypeptide capable of binding to TGF-β for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-β, wherein said polypeptide is capable of inhibiting theinteraction of T...  
WO/2018/130184A1
The present invention relates to a 1,2,4-triazine-3-amine derivative, a preparation therefor, and use thereof in medicine. Specifically, the present invention relates to a 1,2,4-triazine-3-amine derivative as represented by general formu...  
WO/2018/132279A1
The invention relates generally to compounds of formula (I) that modulate the activity of TGFβR-l and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysre...  
WO/2018/130679A1
The present invention relates to a method for reducing CD95-mediated cell motility. To identify chemicals disrupting CD95/PLCγ1 interaction, the inventors screened a chemical library of EMA/FDA-approved molecules against a protein-fragm...  
WO/2018/130108A1
Provided is an application method of a cellular vesicle in the preparation of an oral tumor vaccine. The oral tumor vaccine is a cellular vesicle derived from an apoptotic tumor cell. A subject to be immunized is firstly subjected to ant...  
WO/2018/132539A1
Provided are methods of increasing innate and adaptive immune activation in a human subject by administering a composition comprising the TLR7/8 agonist MED 19197, preferably via intratumoral injection into a cutaneous or subcutaneous tu...  
WO/2018/129622A1
Provided herein are compositions, method and uses for modulating IAP activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (dASO) for administration to a cancer cell, wherein the can...  
WO/2018/130625A1
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...  
WO/2018/132518A1
Provided herein are methods of identifying genomic region(s) predictive of an outcome of treatment with a cell therapy and/or of a phenotype of function of the cells. In some embodiments, the methods include epigenetic and/or epigenomic ...  
WO/2018/129618A1
The present disclosure relates to compounds of Formula (I) which are multimeric forms of a monomeric binding peptide linearly bonded to PEG moieties to form the multimers. The multimeric forms stimulate angiogenesis and promote wound hea...  
WO/2018/130213A1
Disclosed are an imidazopyrazine compound, a preparation method therefor and use thereof. Specifically, disclosed are a compound having a structure as represented by formula (I), a pharmaceutically acceptable salt, a stereoisomer or a pr...  
WO/2018/130661A1
A drug delivery system and methods of using such for delivering a PEGylated therapeutic agent to brain. The drug delivery system may comprise an antibody, which binds polyethylene glycol (PEG), wherein the antibody is embedded in a hydro...  
WO/2018/132751A1
A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrog...  
WO/2018/132559A1
The present invention provides compositions and methods for treating cancer.  
WO/2018/130150A1
The present invention discloses a method for treating cancer metastasis by using IL-35 antagonist and composition thereof.  
WO/2018/132496A1
Provided are multi-arm polymer conjugates of Toll-Like Receptor ("TLR") agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula ...  
WO/2018/130123A1
The present invention falls within the field of medical chemistry, and relates to a pentacyclic compound as a selective estrogen receptor down-regulator and the use thereof. In particular, provided in the present invention are a compound...  
WO/2018/130124A1
The present invention falls within the field of medical chemistry, and relates to a tricyclic compound as a selective estrogen receptor down-regulator and the use thereof. In particular, provided in the present invention are a compound a...  
WO/2018/129645A1
The present invention found that lasofoxifene is an antagonist of ER-α36. It not only inhibits the growth of ER-α36 positive lung, colon and gastric cancers, and also it can inhibit the growth of acquired or de novo tamoxifen-resistant...  
WO/2018/130174A1
Disclosed are a pyrrolo[2,3-c]pyridine derivative, a preparation method therefor, and use thereof in medicine. Specifically, disclosed are a pyrrolo[2,3-c]pyridine derivative as represented by general formula (1), a preparation method th...  
WO/2018/130928A1
A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acc...  
WO/2018/131626A1
The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention pro...  
WO/2018/130155A1
Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a ...  
WO/2018/132636A1
The present invention provides a compound having the structure: (Formula I), and a method of inhibiting Glycogen synthase kinase-3 β (GSK-3β) in a subject comprising administering to the subject said compound, so as to thereby inhibit ...  
WO/2018/130869A1
This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment a...  
WO/2018/129535A1
Provided herein are methods and kits for determining the presence or absence of certain microRNA biomarkers in a blood sample of a female patient. The microRNA biomarkers are associated with ovarian cancer. Also provided are methods for ...  
WO/2018/126317A1
Compositions and methods for treating cancer in humans are provided using CARs. The invention includes engineered CARs (chimeric receptor antigens) and genetically modified immune cells that express such a CAR with a high affinity for VE...  
WO/2018/126595A1
The present application provides an antibody or antibody fragment capable of binding to a lung-specific X protein and being used to treat a tumor, and a use thereof. The antibody or antibody fragment includes heavy chain CDRs having amin...  
WO/2018/129227A1
The present disclosure relates to solid state forms of Selinexor, processes for preparation thereof and pharmaceutical compositions thereof.  
WO/2018/129553A1
The present disclosure provides methods of administering certain TIM-3 binding agents to patients having cancer. Dosage regimens for compositions comprising a TIM-3 binding agent are also explicitly provided.  
WO/2018/129399A1
Provided herein is a novel method for creating fixed, non-antagonistic molar ratios of drugs in and around the bone environment for desired periods of time. This method enables treating bone and bone-related disease by administering a ph...  
WO/2018/127130A1
Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2018/129202A1
Described herein are compositions and methods for treating a disease, particularly a cancer, with a Dengue Virus and, optionally, primed dendritic cells recognizing a tumor antigen. Lysis protocols are described where the lysis does not ...  
WO/2018/128173A1
The present disclosure relates to methods of treating prostate cancer by administering an effective amount of sirolimus locally to the prostate of a subject in need thereof. In particular, the present disclosure provides methods of treat...  
WO/2018/127082A1
A method of treating refractory or resistant pancreatic cancer by administering: (i) a cationic liposomal formulation comprising one or more cationic lipids and a therapeutically effective amount of paclitaxel; or (ii) a cationic liposom...  
WO/2018/127053A1
Provided are a therapeutic agent comprising oncolytic viruses and NK cells and an application thereof in drugs for treating tumors and/or cancer. Active ingredients of the therapeutic agent comprise oncolytic viruses and NK cells, the on...  
WO/2018/126898A1
The present invention provides a thienopyrimidine derivative, a preparation method therefor, and an application thereof in manufacturing of antitumor drugs. The derivative has a structure as represented by general formula (I), comprising...  
WO/2018/127699A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2018/129381A1
Disclosed herein are compounds that can bind to tubulin and activate GEF-Hl. Methods of using these compounds for treating cancer are also disclosed.  
WO/2018/127917A1
PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 ami...  
WO/2018/129306A1
Provided herein are recombinant fusion polypeptides comprising an HPV16 antigenic peptide and an HPV18 antigenic peptide, wherein the HPV16 antigenic peptide and the HPV18 antigenic peptide are operably linked in tandem (e.g., fused to a...  
WO/2018/126673A1
An application of albiflorin or a pharmaceutically acceptable salt thereof as an IDO inhibitor; albiflorin or a pharmaceutically acceptable salt thereof serving as an IDO inhibitor can be used for preparing a drug, food, health product, ...  
WO/2018/127787A1
Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4- 1BB antibody, where said features may improve certain characteristics of the antibody rel...  

Matches 1 - 50 out of 157,231